Diabetics, beware! A U.S. study has highlighted that two drugs widely used in the treatment of diabetes may double the risk of cardiovascular disease.
The Avendia and Actos, two drugs widely prescribed to diabetics, are they safe? Not if we believe the results of a new U.S. study. The latter claims that these two drugs would double the risk of suffering from heart failure!
The team of Prof. Sonal Sing followed 78,000 diabetes patients treated with Avandia (rosiglitazone) or Actos (pioglitazone). His verdict is extremely disquieting: these molecules would double the risk of suffering heart failure. “We knew that Actos and Avendia increased cardiovascular risk,” said Dr. Singh, but the risk we have calculated is much higher than was hitherto assumed. “Statistically, the researchers believe that 50 patients subjected to these treatments, one will develop heart failure within 26 months.
The researchers also found that this risk existed even when the drugs are taken in low doses. Another lesson from this study: one is immune to heart failure caused by this anti-diabetes. Indeed, even among younger patients who have no risk factors, cardiovascular risk skyrockets? 25% of diabetics under 60 years or under Actos Avendia have developed heart failure.
In light of these results, experts recommend that physicians review their requirements with particular attention given to patients with other cardiovascular risk factors.
Tags: Actos and Avendia increased cardiovascular risk, Anti Diabetes Drugs, Avandia (rosiglitazone) or Actos (pioglitazone), cardiovascular risk factors, heart failure, Treatment of Diabetes
